These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 16525679)
1. Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation. Kitabayashi H; Shimada H; Yamada S; Yasuda S; Kamata T; Ando K; Tsujii H; Ochiai T Oncol Rep; 2006 Apr; 15(4):913-8. PubMed ID: 16525679 [TBL] [Abstract][Full Text] [Related]
2. Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Kano M; Yamada S; Hoshino I; Murakami K; Akutsu Y; Sakata H; Nishimori T; Usui A; Miyazawa Y; Kamada T; Tsujii H; Matsubara H Anticancer Res; 2009 Nov; 29(11):4433-8. PubMed ID: 20032389 [TBL] [Abstract][Full Text] [Related]
3. Growth suppression of esophageal squamous cell carcinoma induced by heavy carbon-ion beams combined with p53 gene transfer. Oohira G; Yamada S; Ochiai T; Matsubara H; Okazumi S; Ando K; Tsujii H; Hiwasa T; Shimada H Int J Oncol; 2004 Sep; 25(3):563-9. PubMed ID: 15289857 [TBL] [Abstract][Full Text] [Related]
4. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy. Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815 [TBL] [Abstract][Full Text] [Related]
5. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Tanaka E; Hashimoto Y; Ito T; Kondo K; Higashiyama M; Tsunoda S; Ortiz C; Sakai Y; Inazawa J; Shimada Y Clin Cancer Res; 2007 Feb; 13(4):1331-40. PubMed ID: 17317845 [TBL] [Abstract][Full Text] [Related]
6. [Antitumor effect of docetaxel against human esophagus tumor cell lines and tumor xenografts in nude mice]. Shakuto S; Fujita F; Fujita M Gan To Kagaku Ryoho; 2006 Mar; 33(3):337-43. PubMed ID: 16531714 [TBL] [Abstract][Full Text] [Related]
7. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878 [TBL] [Abstract][Full Text] [Related]
8. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384 [TBL] [Abstract][Full Text] [Related]
9. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Zhao T; Chen H; Zhang T Med Oncol; 2012 Dec; 29(5):3017-23. PubMed ID: 22476809 [TBL] [Abstract][Full Text] [Related]
10. Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs. Xie L; Song X; Yu J; Wei L; Song B; Wang X; Lv L J Exp Clin Cancer Res; 2009 May; 28(1):68. PubMed ID: 19470182 [TBL] [Abstract][Full Text] [Related]
11. [Efficacy and side-effects of docetaxel combined with cisplatin on the treatment of local advanced esophageal cancer with concomitant radiation therapy]. Zhang TR; Zhao T; Xu X; Gu XW; Pan YK Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):791-4. PubMed ID: 21163074 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma. Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629 [TBL] [Abstract][Full Text] [Related]
13. Adenovirus-mediated FIR demonstrated TP53-independent cell-killing effect and enhanced antitumor activity of carbon-ion beams. Kano M; Matsushita K; Rahmutulla B; Yamada S; Shimada H; Kubo S; Hiwasa T; Matsubara H; Nomura F Gene Ther; 2016 Jan; 23(1):50-6. PubMed ID: 26241176 [TBL] [Abstract][Full Text] [Related]
14. A microemulsion co-loaded with Schizandrin A-docetaxel enhances esophageal carcinoma treatment through overcoming multidrug resistance. Su X; Gao C; Shi F; Feng X; Liu L; Qu D; Wang C Drug Deliv; 2017 Nov; 24(1):10-19. PubMed ID: 28155336 [TBL] [Abstract][Full Text] [Related]
15. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma. Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813 [TBL] [Abstract][Full Text] [Related]
16. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy. Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183 [TBL] [Abstract][Full Text] [Related]
17. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment. Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336 [TBL] [Abstract][Full Text] [Related]
18. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. Mynhardt C; Damelin LH; Jivan R; Peres J; Prince S; Veale RB; Mavri-Damelin D J Cell Biochem; 2018 Jan; 119(1):1193-1203. PubMed ID: 28722177 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of neoadjuvant chemotherapy with docetaxel, nedaplatin, and S1 for advanced esophageal squamous cell carcinoma. Tanaka Y; Yoshida K; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K Cancer Sci; 2016 Jun; 107(6):764-72. PubMed ID: 27061001 [TBL] [Abstract][Full Text] [Related]
20. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma. Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]